



FORESIGHT BIOTHERAPEUTICS ANNOUNCES FST-100 DISPLAYS ROBUST CLINICAL IMPROVEMENT IN ADENOVIRAL CONJUNCTIVITIS MODEL

- *Dramatically reduces clinical signs in a highly regarded rabbit model of adenoviral conjunctivitis*
- *Study demonstrates that FST-100 provided rapid and statistically significant clinical improvement over both placebo and active controls*
- *No safety issues identified*

NEW YORK, NY, July 8, 2009 – Foresight Biotherapeutics, Inc. today announced data from a pre-clinical study designed to assess the safety and efficacy of the topical administration of FST-100 in a highly regarded Ad5 NZW rabbit model of adenoviral conjunctivitis. FST-100 demonstrated a clinically and statistically significant reduction in signs of adenoviral conjunctivitis versus all other groups including the current experimental “gold standard”, topical cidofovir. The study was conducted at the Louisiana State University (LSU) Health Science Center, LSU Eye Center in New Orleans, Louisiana by Professor James M. Hill and colleagues, in the Departments of Pharmacology, Microbiology, Ophthalmology and Neuroscience.

The randomized controlled study was conducted in 40 eyes of 20 rabbits experimentally inoculated with human adenovirus type 5. The study was designed to investigate the safety and efficacy of topically administered FST-100 compared to both active controls and to placebo. Animals were randomized 1:1:1:1 (5 rabbits per group) to FST-100, topical 0.5% cidofovir, Tobradex® (tobramycin/dexamethasone) ophthalmic suspension and placebo. Treatment began one day after viral inoculation and continued for 8 days. Eyes were scored daily for clinical parameters including conjunctival inflammation, fragility of ocular blood vessels, purulent discharge, eyelid inflammation, and excessive tearing. Daily viral titer data using a plaque reduction assay are currently undergoing analysis.

The study concluded that FST-100 was superior to all other arms of the study. Dramatic clinical improvement was seen in some treated rabbits as early as 48 hours after the first dose of FST-100. Complete clinical resolution was observed in all FST-100 treated eyes. No other group reached complete clinical resolution. Specifically, treatment with cidofovir, Tobradex® or placebo resulted in injected and inflamed corneas, eyelid and conjunctival inflammation and injection with sub-conjunctival heme.

Professor Hill commented, “This set of data using FST-100 in this very challenging animal model of adenoviral conjunctivitis is highly encouraging. Specifically, no other drug that I have tested has provided such dramatic clinical efficacy, indicating that further studies in human adenoviral conjunctivitis are certainly warranted.”

About Foresight Biotherapeutics, Inc.

Foresight Biotherapeutics is a drug development company focused on diseases of the eye and ear. The company’s website is: www.foresightbiotherapeutics.com.

For further information contact:

Investor Relations, Foresight Biotherapeutics
646-747-9100 or admin@foresightbio.com

Safe Harbor Statement Regarding Forward-looking Statements

The statements in this release and oral statements made by representatives of Foresight relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Foresight's product candidates are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Foresight and/or its partners to develop, manufacture and commercialize, Foresight's ability to fund such efforts with or without partners, and other risks.

#